Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:ALDX

Aldeyra Therapeutics Q1 2025 Earnings Report

Aldeyra Therapeutics logo
$1.73 0.00 (0.00%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$1.74 +0.02 (+0.87%)
As of 05/8/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Aldeyra Therapeutics EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Aldeyra Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
($0.80) million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aldeyra Therapeutics Announcement Details

Quarter
Q1 2025
Date
5/14/2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Aldeyra Therapeutics' Q2 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Aldeyra Therapeutics' Q1 2025 Quarterly reportQuarterly report
(10-Q)

Aldeyra Therapeutics Earnings Headlines

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 8 at 9:36 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291158/0/en/aldx-investors-have-opportunity-to-lead-aldeyra-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm.html
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
May 8 at 9:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291118/0/en/aldx-deadline-the-gross-law-firm-reminds-aldeyra-therapeutics-inc-investors-of-upcoming-securities-class-action-deadline.html
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 9 at 1:00 AM  |  American Alternative (Ad)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
May 7 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-aldeyra-therapeutics-inc-of-class-action-lawsuit-and-upcoming-deadlines--aldx-302765117.html
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Clinical Trial Results: SueWallSt
May 7 at 9:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/aldx-investor-alert-aldeyra-therapeutics-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-company-allegedly-misrepresented-clinical-trial-results-suewallst-302765084.html
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
May 6 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3289151/9788/en/bronstein-gewirtz-grossman-llc-urges-aldeyra-therapeutics-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
See More Aldeyra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aldeyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your email.

About Aldeyra Therapeutics

Aldeyra Therapeutics (NASDAQ:ALDX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis. Aldeyra is also developing ADX-2191, an intravitreal formulation targeting proliferative vitreoretinopathy, a serious complication of retinal detachment surgery. In addition to its ophthalmology pipeline, Aldeyra has earlier-stage programs exploring systemic indications where reactive aldehyde species contribute to inflammation and tissue damage.

Founded in 2009 and headquartered in Lexington, Massachusetts, Aldeyra is led by a management team with extensive experience in ophthalmology and biopharmaceutical development. Under the leadership of Chief Executive Officer Fredric A. Hargreaves, the company collaborates with clinical research centers across North America and Europe to advance its pipeline through late-stage clinical trials. Aldeyra’s strategy emphasizes rigorous clinical validation, strategic partnerships and readiness for commercial launch upon regulatory approval.

View Aldeyra Therapeutics Profile
Earnings Tools